Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections in adults and children when prescribed by a healthcare professional.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is indicated for several bacterial infections affecting the respiratory and skin systems. - Community‑acquired bacterial pneumonia: reduces bacterial load and improves clinical outcomes. - Acute bacterial sinusitis: alleviates sinus inflammation caused by susceptible organisms. - Acute exacerbations of chronic bronchitis: helps restore lung function and reduces symptoms. - Skin and soft‑tissue infections: eradicates susceptible Gram‑positive and some Gram‑negative bacteria. - Helicobacter pylori eradication (in combination therapy): contributes to ulcer healing and infection clearance.

Clarithromycin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools often occurring early in therapy. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: transient mild to moderate headache. - Vomiting: occasional episodes, especially with high doses.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or angioedema requiring immediate medical attention. - QT interval prolongation: may lead to cardiac arrhythmias. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Hepatotoxicity: elevated liver enzymes or jaundice. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Cardiac arrhythmias: irregular heart rhythms beyond QT prolongation.

Before prescribing clarithromycin, clinicians should evaluate patient-specific factors and monitor for potential complications. - Assess liver function: adjust use in hepatic impairment. - Monitor cardiac QT interval: avoid in patients with known prolongation or concurrent QT‑prolonging drugs. - Use caution in renal impairment: dose may need adjustment. - Avoid in known macrolide hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant medications: consider interactions that may alter drug levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Clarithromycin interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Cisapride: risk of serious cardiac arrhythmias. - Pimozide: can cause QT prolongation and torsades de pointes. - Ergot alkaloids (e.g., ergotamine): may precipitate ergotism. - Certain antiarrhythmics (e.g., quinidine): increased plasma concentrations.

Moderate Interactions (Monitor Closely): - Statins (simvastatin, lovastatin): elevated risk of myopathy. - Warfarin: possible increase in anticoagulant effect. - Oral hypoglycemics (e.g., sulfonylureas): enhanced hypoglycemia. - Digoxin: higher serum levels may occur. - Colchicine: dose reduction may be needed to avoid toxicity.